

Potentially Accelerating Transformative Medicines to Market

Guggenheim 3rd Annual Boston Healthcare Conference

Mikael Dolsten, M.D., Ph.D.

President Worldwide R&D

December 15, 2015

Forward-looking Statements

- This presentation includes forward-looking statements about, among other things, development of Pfizer's products and product candidates, including their potential benefits, expected market opportunity and expected regulatory submissions and approvals that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in our subsequent reports on Form 8-K, all of which are filed with the SEC and available at www.sec.gov and www.pfizer.com. The forward-looking statements in this presentation speak only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements.
- These reports are available on our website at www.pfizer.com in the "Investors – SEC Filings" section.

Strong Track Record of Approvals

Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME's)

Prevenar 13

IBRANCE[™]
palbociclib | 125 mg capsules

 **Inlyta**[™]
axitinib tablets

 **XALKORI**[®]
CAPSULES
CRIZOTINIB

XELJANZ[™] 
[tofacitinib citrate]
5 mg tablets

Eliquis[™]
apixaban

Strong Track Record of Approvals

Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME's)



Prevenar 13

A Pneumococcal Vaccine for All Age Groups

CAPiTA adult approval

Strong Track Record of Approvals

Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME's)



IBRANCE™
palbociclib | 125 mg capsules

Approved 1L Adv. Breast Cancer (BC) + Letrozole (US)

Recurrent Adv. BC submission with *priority review (US)*

Phase 3 Start in adjuvant early BC

Strong Track Record of Approvals

Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME's)

Prevenar 13

IBRANCE
palbociclib | 125 mg capsules

 **Inlyta**
axitinib tablets

 **XALKORI**
CAPSULES
CRIZOTINIB

XELJANZ
[tofacitinib citrate]
5 mg tablets

Eliquis
apixaban

 **Inlyta**
axitinib tablets

Approved for adv. renal cell carcinoma (RCC)

Ph 3. Study Adjuvant RCC

Ph. 1 Inlyta[®] + Keytruda[®] shows activity in naïve adv. RCC

Strong Track Record of Approvals

Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME's)



Approved for ALK+ NSCLC

ROS1+ NSCLC Submission with Priority Review (US)

ROS1+ NSCLC Breakthrough Designation

Strong Track Record of Approvals

Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME's)

Prevenar 13

IBRANCE[™]
palbociclib | 125 mg capsules



Inlyta[™]
axitinib tablets

XALKORI[™]
CAPSULES
CRIZOTINIB

XELJANZ[™]
[tofacitinib citrate]
5 mg tablets

Eliquis[™]
apixaban

XELJANZ[™]
[tofacitinib citrate]
5 mg tablets

Approved for treatment of rheumatoid arthritis (RA)

Ph. 3 studies Psoriatic Arthritis & Ulcerative Colitis

QD MR NDA Submission (US)

Strong Track Record of Approvals

Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME's)




*Eliquis*TM
apixaban

Approved for Prevention Atrial Fibrillation

Approved for Treatment of DVT & PE

Robust Pipeline Positioned to Sustain Productivity

Pfizer Pipeline (As of October 27, 2015)



Programs with Accelerated Regulatory Pathways

3

Breakthrough Therapy

e.g., *inotuzumab* (ALL)
avelumab (MCC)
Xalkori® (ROS+ NSCLC)

6

Fast Track Designation

e.g., *S.aureus* Vaccine
C.difficile Vaccine
rivipansel (SCD)

14

Orphan Drug Designation

e.g., *F9 Gene Therapy* (Hemophilia B)
PDE10 (Huntington's Disease)
lorlatinib (ALK+ NSCLC)

Delivering Novel & Differentiated Future Potential Products

Potential for >20 Approvals 2016-20, incl. 7 NMEs



Oncology



Vaccines



Neuroscience



**Inflammation &
Immunology**



Rare Disease



CVMed



Biosimilars

Ibrance® <i>Breast Cancer & Beyond</i>	Nosocomial <i>S.aureus C difficile</i>	Parkinson's <i>Dopamine Modulation Dopamine, GDNF</i>	Xeljanz® LCM <i>QD, RA BID</i>	Sickle Cell <i>rivipansel rivipansel SC, PDE9</i>	Hyperlipidemia <i>bococizumab (PCSK9) mAb, Oral</i>	rituximab
Immuno-Oncology <i>PD-L1/PD-1 4-1BB, OX40, IDO1, CAR-T, IO Combos 4-1BB/rituxan FL</i>	Cancer Vaccines <i>Active immunotherapy</i>	Pain <i>tanezumab</i>	Xeljanz® <i>New Indications UC, Psoriatic Arthritis</i>	Hemophillia <i>Gene Tx F9, TFPI</i>	Type 2 Diabetes <i>SGLT2, Glucagon</i>	bevacizumab
Xalkori® <i>ROS+ NSCLC</i>	Neo. & Older Adults <i>(CMV, RSV, GBS)</i>	Huntington's <i>PDE10</i>	Immuno-kinases <i>Selective JAK's, IRAK4</i>	Growth Hormone <i>LAGH - Ped/Adult</i>		trastuzumab
ADCs <i>inotuzumab ALL PTK7 / EFNA4</i>		Alzheimer's <i>GSM/BACE</i>	Type 1 Diabetes <i>IL7R mAb</i>	Neuromuscular <i>Myostatin DMD</i>		adalimumab
Hematological <i>SMO AML</i>		Cross Domain <i>AMPA</i>				infliximab
Targeted Therapy <i>Lorlatinib NSCLC, Bi-Functional Abs</i>						

Majority of Current Portfolio with Leader-In-Class or Value-In-Class Potential

Delivering Novel & Differentiated Future Potential Products

6 Near-Term Growth Platforms with Potential for Significant Market Opportunity



**Ibrance® Beyond Breast Ca.
& Continued I/O Momentum**

ONCOLOGY

*Lung, PDAC, SCCHN, Melanoma
PD-L1, 41BB, OX40, CAR-T, Combos*



**Accelerating Nosocomial
Vaccines to Market**

VACCINES

*S.aureus
C.difficile*



**Lead in Class
Neuroscience Assets**

NEUROSCIENCE

*Dopamine Modulation
tanezumab anti-NGF*



**Leading JAK Biology
New Indications & MOAs**

INFLAMMATION & IMMUNOLOGY

*Xeljanz®- QD MR, PsA, UC
JAK1, JAK3, Tyk2/JAK1, IRAK4*



**Innovative Therapies in
Hematological Diseases**

RARE DISEASE

*rivipansel, PDE9 SCD
FIX Gene Therapy, TFPI Hemophilia*



**A Differentiated Franchise
Approach to PCSK9**

CVMED

*bococizumab (PCSK9)
mAb, Oral*

Q&A